Abstract PR01: A cancer cell program promotes T-cell exclusion and resistance to checkpoint blockade
Parin Shah(Harvard University), Livnat Jerby‐Arnon(Broad Institute), Shaolin Mei(Harvard University), Charles H. Yoon(Brigham and Women's Hospital), Abhay Kanodia(Dana-Farber Cancer Institute), Bokang Rabasha(Dana-Farber Cancer Institute), Kai W. Wucherpfennig(Dana-Farber Cancer Institute), Dirk Schadendorf(National Center for Tumor Diseases), Asaf Rotem(AstraZeneca (South Korea)), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Johannes C. Melms(Columbia University Irving Medical Center), Rachel Leeson(Dana-Farber Cancer Institute), Benjamin Izar(Columbia University Irving Medical Center), Bruce E. Johnson(Harvard University), Jia‐Ren Lin(Harvard University), Levi A. Garraway(Broad Institute), Peter K. Sorger(Harvard University Press), Orit Rozenblatt–Rosen(Broad Institute), Michael S. Cuoco(Broad Institute), Alex K. Shalek(Broad Institute), Shu Wang(Broad Institute), David Liu(University of Louisville), Aviv Regev(Broad Institute), Mei-Ju Su(Harvard University), Itay Tirosh(Weizmann Institute of Science)
Cited by 1
Related Papers
Full-length transcriptome assembly from RNA-Seq data without a reference genome
|Nature Biotechnology|2011|22.7k
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
De novo transcript sequence reconstruction from RNA-seq using the Trinity platform for reference generation and analysis
|Nature Protocols|2013|9.1k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Spatial reconstruction of single-cell gene expression data
|Nature Biotechnology|2015|7.6k